期刊文献+

NNT和NNH的概念及应用 被引量:10

Something Needed to Pay Attention in the Use of NNT and NNH
下载PDF
导出
摘要 阐述了NNT和NNH的定义和用途。NNT用于治疗前评估不治疗给患者造成损害的可能性,NNH用于评估治疗可能给患者造成伤害的可能性,也可用于比较干预措施与阳性药物比较的相对获益或受损。与安慰剂比较时,NNT或NNH为绝对效应量;与阳性药物比较时,NNT或NNH为相对效应量。当描述相对效应量时,通过RR或OR、RD表示干预措施与对照的效应量大小关系。 NNT defines the number of patients who need to be treated in order to achieve one additional favorable outcome,and NNH is defined as the number of patients who must be treated with a therapy in order to have one additional patient suffer an adverse effect compared with the control treatment. This is the most important thing that should be considered before administering a treatment. NNT can also be used to assess the relative benefit or harm in the comparison of intervention versus positive control. If the effect is smaller in the intervention group than that in the control group,NNT should be used; if the effect is bigger in the intervention group than that in the control group,NNH should be used. When comparison is made between an intervention versus placebo,NNT and NNH are absolute outcomes; when an intervention is compared to a positive control,NNT and NNH are relative outcomes. RR or OR or RD may help to judge which comparator has bigger or smaller effect,and whether NNT or NNH should be used.
出处 《中国循证医学杂志》 CSCD 2007年第9期669-672,共4页 Chinese Journal of Evidence-based Medicine
关键词 NNT NNH 治疗 不治疗 获益 受损 NNT NNH Treatment Untreated Benefit Harm
  • 相关文献

参考文献5

  • 1Andreas L,David L,Sackett RS,et al.An assessment of clinically useful measures of the consequences of treatment.The New Eng J Med,1988,318(26):1728-1733.
  • 2Fletcher RH,Fletcher SW,Wagner EH.Clinical Epidemiology.The Essentials.3rd edition.Williams & Wilkins A Waverly Company.Baltimore,Maryland,USA.
  • 3Gordon Guyatt,Drummond Rennie.Users' Guides to the medical literature.Essentials of Evidence-Based Clinical Practice.JAMA ARCHIVES JORNALS.AMA Press.
  • 4Johansen HK,Gotzsche PC.Amphotericin B versus fluconazole for controlling fungal infections in neutropeniccancer patients.Cochrane Database of SystematicReviews,Issue 2,2002,(2):CD000239.
  • 5吴泰相,刘关键,张鸣敏,王覃,倪娟,魏家富,周礼鲲,段鑫,陈小燕,郑洁,乔杰奇.青蒿素类药物预防日本血吸虫感染效果及安全性的系统评价[J].中华医学杂志,2003,83(14):1219-1224. 被引量:11

二级参考文献22

  • 1吴玲娟,李思温,宣尧仙,徐潘生,刘志德,胡林生,周诗云,邱英席,刘跃民.青蒿琥酯预防日本血吸虫病346例的现场研究[J].中国血吸虫病防治杂志,1995,7(6):323-327. 被引量:18
  • 2肖树华,石中谷,卓尚炯,王存志,张志刚,褚波,郑江,陈名刚.蒿甲醚预防日本血吸虫感染的现场观察[J].中国寄生虫学与寄生虫病杂志,1995,13(3):170-173. 被引量:15
  • 3刘志德 刘红云.口服青蒿琥酯预防血吸虫病现场应用研究[J].南昌大学学报:理科版,1998,22(6):1-1.
  • 4University of Cambridge, Department of Pathology, Schistosomiasis Research Group:Geographical Distribution of Schistosomiasis. http://www.path.cam.ac.uk/~schisto/Background/Distribution.html Last Modified on 5th October 1998.
  • 5Capron A, Dessaint JP, Capron M, et al. Immunity to schistosomes: Progress toward vaccine.Science,1987, 238: 1065-1072.
  • 6Cherfas J. New weapon in the war against schistosomiasis. Science, 1989,246:1242-1242.
  • 7WHO/TDR: WORk plan: Vaccine Discovery Research http://www.who.int/tdr/grants/wORkplans/vaccine.htm.
  • 8Li SW,Wu LJ,Liu ZD,et al.Studies on prophylactic effect of artesunate on schistosomiasi Japonica. Chinese Med J,1996,109:848-853.
  • 9Petras JM, Kyle DE, Gettayacamin M, Young GD, Bacman RA, Webster HK, CORcORan KD, Peggins JO, Vane MA, Brewer TG: Arteether: Risks of two-week administration in Macaca Mulatta. Am J Trop Medicine Hyg, 1997,56: 390-396.
  • 10Smith SL, Sadler CJ, Dodd CC, et al. The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Biochemical Pharmacology,2001,61:409-416.

共引文献10

同被引文献136

引证文献10

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部